(Total Views: 240)
Posted On: 04/08/2022 3:40:31 PM
Post# of 160
NetworkNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic and non-psychedelic molecules for medical use. “Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with mental health and addiction disorders with unmet needs,” the article reads. “Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment of mental health and addiction disorders. … Mydecine’s management is confident that with the investments made so far, coupled with the plans for the future, the company will capitalize on the industry’s growth, achieve significant progression and create value for its shareholders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic and non-psychedelic molecules for medical use. “Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with mental health and addiction disorders with unmet needs,” the article reads. “Mydecine, through its research, has positioned itself to capitalize on the opportunities in the industry, particularly with regards to psychedelic medicine for the treatment of mental health and addiction disorders. … Mydecine’s management is confident that with the investments made so far, coupled with the plans for the future, the company will capitalize on the industry’s growth, achieve significant progression and create value for its shareholders.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
